Tulavi Therapeutics

Tulavi Therapeutics is a private, commercial-stage medical device company based in San Diego, leveraging its proprietary Adaptive Hydrogel Technology to improve outcomes in peripheral nerve surgery. Its lead product, the allay Hydrogel Cap, is the first and only fully absorbable device specifically indicated to reduce the risk of symptomatic neuroma formation, targeting a large market of over 1.8 million annual peripheral nerve procedures. Backed by the Incept accelerator and with initial peer-reviewed clinical data published, Tulavi is positioned to capture share in a space historically reliant on inconsistent surgical techniques.

Proprietary fully absorbable Adaptive Hydrogel Technology (90% water, hydrophilic) that forms instantly in situ, conforms to nerve anatomy, and is engineered to support nerve healing and prevent symptomatic neuromas.

The competitive landscape for neuroma prevention is currently fragmented, relying on non-standardized surgical techniques (e.g., nerve capping with muscle, vein, or other tissues). Tulavi's allay Cap is the first and only fully absorbable device specifically indicated for this purpose, giving it a distinct first-mover advantage. Potential competitors include other medical device companies developing nerve cuff or cap technologies, but none appear to have an identical hydrogel-based, fully absorbable product on the market.